# BCIFlex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bciflex

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.bciflex.com/
- Total disclosed funding: $174M
- Latest round: Series B (Sep 21, 2026)
- Investors on record: 17

## About

Based in Beijing, China, and founded in 2022, Beijing Zhiran Medical Technology Co., Ltd., trading under the name BCIFlex, provides neural interface technologies for the medical device industry. The company's co-founder, Dr. Ying Fang, holds a degree from Harvard University and currently serves as a senior researcher at the Beijing Institute of Brain Science and Brain-Inspired Intelligence; another co-founder, Qi Song, previously worked at HeartFlow—a US-based AI medical "unicorn".

In September 2026, BCIFlex raised CNY 600 million in Series B funding from Shunxi Fund, Jifeng Ventures, Legend Capital, HSG, China Life Capital, YuanBio Venture, Shunwei Capital, Long Z Investment, Zhongguancun Science City Capital, Apricot Capital, Shenzhen Jiayin Fund Management, Casstar Capital, Huagai Capital, and other investors.

BCIFlex works with research hospitals and neurosurgical centers to provide precision neural interface systems. The company's offerings include 
digital EEG (electroencephalogram) machine, SEEG (stereo-electroencephalography) electrodes, implantable flexible brain-computer interface system, stretchable high-throughput flexible electrodes, etc.

The company generates revenue from the sale of BCI interface hardware and specialized electrode arrays to clinical institutions and research laboratories. 

The proceeds from the Series B funding round are expected to be allocated by the company to the clinical advancement of the pipeline, the construction of GMP production capacity, and building out the commercialization team.

## Funding rounds

- Series B, Sep 21, 2026, $89M — Legend Capital, Shunwei Capital, Huagai Capital, YuanBio Venture, Casstar Capital, Long Z Investment, Apricot Capital, HSG, Redhill Capital, Shunxi Fund, Shenzhen Jiayin Fund Management, Zhongguancun Science City Capital, Jifeng Ventures, China Life Capital
- Series A, Feb 11, 2026, $43M — Legend Capital, IDG Capital, Shunwei Capital, YuanBio Venture, Lenovo Capital and Incubator Group, Baidu Ventures, Casstar Capital, Long Z Investment, Apricot Capital, HSG, Shunxi Fund, Shenzhen Jiayin Fund Management
- Series A, Aug 12, 2025, $42M — Legend Capital, IDG Capital, YuanBio Venture, Lenovo Capital and Incubator Group, Long Z Investment, Shunxi Fund, China Life Capital

## Investors

- Legend Capital — Series A, Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A, Series B
- Lenovo Capital and Incubator Group (https://capitalatlas.ai/funds/lenovo-capital-and-incubator-group) — Series A
- Long Z Investment (https://capitalatlas.ai/funds/long-z-investment) — Series A, Series B
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series A, Series B
- China Life Capital — Series A, Series B
- Shunwei Capital (https://capitalatlas.ai/funds/shunwei-capital) — Series A, Series B
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A, Series B
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A, Series B
- HSG (https://capitalatlas.ai/funds/hsg) — Series A, Series B
- Shenzhen Jiayin Fund Management — Series A, Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series B
- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Series B
- Zhongguancun Science City Capital (https://capitalatlas.ai/funds/zhongguancun-science-city-capital) — Series B
- Jifeng Ventures (https://capitalatlas.ai/funds/jifeng-ventures) — Series B